Thank you @NiuSanford ! Congrats to the @WashUMedRadOnc team for providing these additional data to guide treatment for this very challenging clinical scenario.
SBRT (50Gy/5fx, MR adaptive) in locally recurrent PDAC.View quoted post on X
N=46 (7 w prior RT). 1 year LC 73%, median OS 19 mo.
Ablative RT = feasible, safe in locally recurrent setting & can confer long term dz control.
Great to see this data published - congrats @adapthyun & team! @OncoAlert